Can we crystallize the role of urate-lowering treatment in chronic kidney disease?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39984252.
- Also identified by DOI 10.1016/j.kint.2024.11.025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The therapeutic value of serum urate lowering in chronic kidney disease is questionable given the lack of clinical benefit from randomized clinical trials. Post hoc analysis of the CARES (Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities) trial suggests a protective effect of urate lowering in gout participants over 2.5 years of follow-up with the greatest benefit for those who maintained average urate levels of <6 mg/dl. A shift in research focus from asymptomatic hyperuricemia to symptomatic hyperuricemia may yet yield dividends.
Medical subject headings
- Uric Acid
- Renal Insufficiency, Chronic
- Hyperuricemia
- Gout Suppressants
- Gout